Latest K-V Pharmaceutical Co. Cl A (KVPHQ) Headlin
Post# of 1
Posted On: 03/10/2014 9:51:35 AM
Latest K-V Pharmaceutical Co. Cl A (KVPHQ) Headlines
Labaton Sucharow LLP Announces Summary Notice of Pendency of Class Action and Proposed Settlement and Motion for Attorneys' Fees and Expenses in Public Pension Fund Group, et al. v. KV Pharmaceutical Company, et al. (08-CV-1859) (E.D. Mo.)
PR Newswire - Wed Mar 05, 8:00AM CST
TO: ALL PERSONS OR ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED THE PUBLICLY TRADED SECURITIES OF KV PHARMACEUTICAL COMPANY ("KV," "K-V," OR THE "COMPANY") DURING THE PERIOD BETWEEN JUNE 15, 2004 AND JANUARY 23, 2009, INCLUSIVE (THE "CLASS PERIOD"), AND WERE ALLEGEDLY DAMAGED THEREBY (THE "CLASS").
Win In Asia By Using Asia - Strategic Supply Chain Is The Key To Global Transformation
PR Newswire - Fri Jan 24, 8:37AM CST
"Asia is changing. Just to be in Asia is not enough anymore. In order to win in Asia you have to use Asia to win." This is the conclusion Steven Tseng, PwC's Global Leader for Value Chain Transformation, drew from the exclusive breakfast dialogue organized by InvestKL, Malaysia's capital city-investment agency, at the World Economic Forum in Davos, Switzerland yesterday. Titled as - 'Global supply chain transformation - strategies for success', the program covered latest trends impacting global companies' operations strategies especially in driving their asset footprint decisions - both for "hard" and "soft" assets.
KV Pharmaceutical Company Completes New Board with Appointment of Former Johnson & Johnson Executive
PR Newswire - Tue Nov 05, 8:00AM CST
K-V Pharmaceutical Company ("KV") today announced the appointment of Janet Vergis to its Board of Directors. Ms. Vergis currently serves as the Executive-In-Residence at Warburg Pincus, LLC. Previously, she was the CEO of OraPharma, Inc. where she led the company's successful turnaround. Prior to her role at OraPharma, Ms. Vergis managed a $6 billion portfolio at Johnson & Johnson as President of Janssen Pharmaceuticals, McNeil Pediatrics, and Ortho-McNeil Neurologics. Ms. Vergis also contributed to a number of Johnson & Johnson companies during her career, serving as a member of company management boards for more than 10 years and holding positions of increasing responsibility in research and development, new product development, sales, and marketing.
KV Pharmaceutical Company Appoints Two New Board Members
PR Newswire - Fri Oct 11, 8:00AM CDT
K-V Pharmaceutical Company ("KV") today announced the appointment of two new members to its Board of Directors: Gregory Norden, former Senior Vice President and Chief Financial Officer for Wyeth Corporation, and James M. Goldfarb, MD, MBA, Director of Infertility Services of the University Hospitals of Cleveland Health Systems and Clinical Professor of Reproductive Biology at Case Western Reserve University (CWRU) School of Medicine.
KV Pharmaceutical Company Completes Reorganization And Successfully Emerges From Chapter 11 With $375 Million Recapitalization
PR Newswire - Mon Sep 16, 9:26AM CDT
K-V Pharmaceutical Company ("KV") today announced that its plan of reorganization (the "Plan") has become effective and that it has successfully emerged from chapter 11 with significantly reduced debt and a $375 million recapitalization.
Ther-Rx Corporation Announces the Availability of Clindesse® (Clindamycin Phosphate) Vaginal Cream, 2% for Prescribing
PR Newswire - Mon Aug 05, 8:50AM CDT
Ther-Rx Corporation, a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace: KVPHQ/KVPBQ) announced today that Clindesse® (clindamycin phosphate) Vaginal Cream, 2% indicated for the treatment of bacterial vaginosis (BV) in non-pregnant women, is now available for prescribing. Wholesalers have ordered and received product and are distributing to retail pharmacies.
K-V Pharma says Hologic settlement approved
AP - Fri Dec 28, 12:30PM CST
ST. LOUIS (AP) — A settlement between K-V Pharmaceutical Co. and Hologic has been approved by a bankruptcy court.
K-V Pharmaceutical Receives Court Approval of Hologic Settlement
PR Newswire - Fri Dec 28, 11:43AM CST
K-V Pharmaceutical Company ("K-V" or "the Company") today announced that the U. S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding, approved the Company's settlement agreement with Hologic, Inc. ("Hologic Settlement"), and authorized the Company to enter into an $85 million debtor-in-possession ("DIP") financing to, among other things, fund the settlement.
Labaton Sucharow LLP Announces Summary Notice of Pendency of Class Action and Proposed Settlement and Motion for Attorneys' Fees and Expenses in Public Pension Fund Group, et al. v. KV Pharmaceutical Company, et al. (08-CV-1859) (E.D. Mo.)
PR Newswire - Wed Mar 05, 8:00AM CST
TO: ALL PERSONS OR ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED THE PUBLICLY TRADED SECURITIES OF KV PHARMACEUTICAL COMPANY ("KV," "K-V," OR THE "COMPANY") DURING THE PERIOD BETWEEN JUNE 15, 2004 AND JANUARY 23, 2009, INCLUSIVE (THE "CLASS PERIOD"), AND WERE ALLEGEDLY DAMAGED THEREBY (THE "CLASS").
Win In Asia By Using Asia - Strategic Supply Chain Is The Key To Global Transformation
PR Newswire - Fri Jan 24, 8:37AM CST
"Asia is changing. Just to be in Asia is not enough anymore. In order to win in Asia you have to use Asia to win." This is the conclusion Steven Tseng, PwC's Global Leader for Value Chain Transformation, drew from the exclusive breakfast dialogue organized by InvestKL, Malaysia's capital city-investment agency, at the World Economic Forum in Davos, Switzerland yesterday. Titled as - 'Global supply chain transformation - strategies for success', the program covered latest trends impacting global companies' operations strategies especially in driving their asset footprint decisions - both for "hard" and "soft" assets.
KV Pharmaceutical Company Completes New Board with Appointment of Former Johnson & Johnson Executive
PR Newswire - Tue Nov 05, 8:00AM CST
K-V Pharmaceutical Company ("KV") today announced the appointment of Janet Vergis to its Board of Directors. Ms. Vergis currently serves as the Executive-In-Residence at Warburg Pincus, LLC. Previously, she was the CEO of OraPharma, Inc. where she led the company's successful turnaround. Prior to her role at OraPharma, Ms. Vergis managed a $6 billion portfolio at Johnson & Johnson as President of Janssen Pharmaceuticals, McNeil Pediatrics, and Ortho-McNeil Neurologics. Ms. Vergis also contributed to a number of Johnson & Johnson companies during her career, serving as a member of company management boards for more than 10 years and holding positions of increasing responsibility in research and development, new product development, sales, and marketing.
KV Pharmaceutical Company Appoints Two New Board Members
PR Newswire - Fri Oct 11, 8:00AM CDT
K-V Pharmaceutical Company ("KV") today announced the appointment of two new members to its Board of Directors: Gregory Norden, former Senior Vice President and Chief Financial Officer for Wyeth Corporation, and James M. Goldfarb, MD, MBA, Director of Infertility Services of the University Hospitals of Cleveland Health Systems and Clinical Professor of Reproductive Biology at Case Western Reserve University (CWRU) School of Medicine.
KV Pharmaceutical Company Completes Reorganization And Successfully Emerges From Chapter 11 With $375 Million Recapitalization
PR Newswire - Mon Sep 16, 9:26AM CDT
K-V Pharmaceutical Company ("KV") today announced that its plan of reorganization (the "Plan") has become effective and that it has successfully emerged from chapter 11 with significantly reduced debt and a $375 million recapitalization.
Ther-Rx Corporation Announces the Availability of Clindesse® (Clindamycin Phosphate) Vaginal Cream, 2% for Prescribing
PR Newswire - Mon Aug 05, 8:50AM CDT
Ther-Rx Corporation, a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace: KVPHQ/KVPBQ) announced today that Clindesse® (clindamycin phosphate) Vaginal Cream, 2% indicated for the treatment of bacterial vaginosis (BV) in non-pregnant women, is now available for prescribing. Wholesalers have ordered and received product and are distributing to retail pharmacies.
K-V Pharma says Hologic settlement approved
AP - Fri Dec 28, 12:30PM CST
ST. LOUIS (AP) — A settlement between K-V Pharmaceutical Co. and Hologic has been approved by a bankruptcy court.
K-V Pharmaceutical Receives Court Approval of Hologic Settlement
PR Newswire - Fri Dec 28, 11:43AM CST
K-V Pharmaceutical Company ("K-V" or "the Company") today announced that the U. S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding, approved the Company's settlement agreement with Hologic, Inc. ("Hologic Settlement"), and authorized the Company to enter into an $85 million debtor-in-possession ("DIP") financing to, among other things, fund the settlement.
(0)
(0)K-V Pharmaceutical Company (KVPHQ) Stock Research Links
Scroll down for more posts ▼